Table 1

Effects of CPENSpm and chemotherapeutic drugs on MCF-7 cellsa

DrugFractional growth inhibitionb
0.500.750.90
Concomitant CPENSpm+ drug
Doxorubicin1.13 ± 0.161.04 ± 0.180.99 ± 0.27
c-DDP1.08 ± 0.130.95 ± 0.180.88 ± 0.22
5-FU0.69 ± 0.420.75 ± 0.231.27 ± 0.62
Vinorelbine0.73 ± 0.370.67 ± 0.290.68 ± 0.27
Paclitaxel1.16 ± 0.111.12 ± 0.141.12 ± 0.16
Docetaxel0.93 ± 0.070.83 ± 0.250.80 ± 0.38
Drug then CPENSpm
Doxorubicin0.84 ± 0.080.65 ± 0.090.51 ± 0.08
c-DDP0.85 ± 0.110.69 ± 0.130.63 ± 0.19
5-FU0.58 ± 0.130.49 ± 0.120.42 ± 0.12
FdUrd0.67 ± 0.160.54 ± 0.080.47 ± 0.11
4HC0.93 ± 0.120.77 ± 0.160.67 ± 0.22
Vinorelbine0.30 ± 0.290.32 ± 0.200.43 ± 0.06
Paclitaxel0.74 ± 0.140.68 ± 0.110.67 ± 0.05
Docetaxel0.82 ± 0.150.66 ± 0.190.54 ± 0.21
CPENSpm then CPENSpm and drug
Doxorubicin1.08 ± 0.270.88 ± 0.180.76 ± 0.13
c-DDP1.17 ± 0.190.84 ± 0.070.64 ± 0.07
5-FU0.88 ± 0.140.81 ± 0.190.85 ± 0.42
Vinorelbine0.74 ± 0.330.77 ± 0.270.89 ± 0.37
Paclitaxel0.99 ± 0.130.82 ± 0.140.69 ± 0.15
Docetaxel0.69 ± 0.290.58 ± 0.200.50 ± 0.15
  • a Results are shown for combination studies using the polyamine analog, CPENSpm, and drug at three different treatment schedules.

  • b CI values for fractional growth inhibitions of 0.50, 0.75, and 0.90 in the MCF-7 cell line. Antagonism CI > 1.00; additivity CI = 1.00; synergy CI < 1.00 ± SD.